摘要
细胞毒性T细胞相关抗原4(cytotoxic T-lymphocyte-associated protein 4,CTLA-4)、程序性死亡受体1(programmed cell death protein-1,PD-1)/程序性死亡配体1(programmed cell death ligand-1,PD-L1)是近年研究比较透彻的免疫检查点(immune checkpoint,IC),新兴的IC如淋巴细胞激活基因3(lymphocyte activationgene 3,LAG-3)、B7H3正在研究中。多项临床研究证实,针对CTLA-4、PD-1/PD-L1免疫检查点的抑制剂(immune checkpoint inhibitor,ICI)在抑制肿瘤生长、维持疾病稳定及延长患者生存时间上取得了令人瞩目的效果,因此ICI有望在儿童恶性肿瘤治疗中发挥一定的作用。但ICI也具有一定局限性,包括疗效不确切及不良反应。如何确定最佳的受益人群,使患者获益最大、风险最小,是未来的研究方向。
Cytotoxic T-lymphocyte-associated protein 4(CTLA-4), programmed cell death protein-1(PD-1)and programmed cell death ligand-1(PD-L1)are well studied immune checkpoint(IC)in recent years.New IC, such as lymphocyte activation gene 3(LAG-3)and B7H3 are in progress.Several clinical trials have confirmed that inhibitors of CTLA-4 and PD-1/PD-L1 have achieved remarkable results in inhibiting tumor growth, maintaining disease stability and prolonging survival of patients.Therefore, immune checkpoint inhibitor(ICI)is expected to play a potential role in the treatment of malignant tumors in children.However, ICI also has some limitations, including uncertain efficacy and potential toxicity.It is challenging to identify the best target population, maximize the benefit of patients and minimize the risk of toxicity in future.
作者
廖茹(综述)
张伟令
胡慧敏
黄东生(审校)
Liao Ru;Zhang Weiling;Hu Huimin;Huang Dongsheng(Department of Pediatrics,Beijing Tongren Hospital,Capital Medical University,Beijing 100176,China)
出处
《国际儿科学杂志》
2019年第1期53-56,共4页
International Journal of Pediatrics
